Targeting CD137 enhances the efficacy of cetuximab
2014
Treatment with
cetuximab, an EGFR-targeting IgG1 mAb, results in beneficial, yet limited, clinical improvement for patients with head and neck (HN) cancer as well as colorectal cancer (CRC) patients with WT
KRAStumors.
Antibody-dependent cell-mediated cytotoxicity(ADCC) by NK cells contributes to the efficacy of
cetuximab. The costimulatory molecule
CD137(4-1BB) is expressed following NK and
memory T cellactivation. We found that isolated human NK cells substantially increased expression of
CD137when exposed to
cetuximab-coated, EGFR-expressing HN and CRC cell lines. Furthermore, activation of
CD137with an agonistic mAb enhanced NK cell
degranulationand cytotoxicity. In multiple murine xenograft models, including EGFR-expressing cancer cells, HN cells, and
KRAS-WT and
KRAS-mutant CRC, combined
cetuximaband anti-
CD137mAb administration was synergistic and led to complete tumor resolution and prolonged survival, which was dependent on the presence of NK cells. In patients receiving
cetuximab, the level of
CD137on circulating and intratumoral NK cells was dependent on postcetuximab time and host FcyRIIIa polymorphism. Interestingly, the increase in
CD137-expressing NK cells directly correlated to an increase in EGFR-specific CD8+ T cells. These results support development of a sequential antibody approach against EGFR-expressing malignancies that first targets the tumor and then the host immune system.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
58
References
140
Citations
NaN
KQI